Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

f cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The American Association for Homecare ... and Manufacturing has joined the AAHomecare Corporate Partner Program. ... Diamond have been actively involved in AAHomecare for ... has quickly grown into a major global manufacturer of ... allows AAHomecare to increase efforts on behalf of the ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
(Date:9/21/2014)... 21, 2014 The Electronic Medical ... supports electronic medical records (EMR) and electronic health ... healthcare legislation during the past five years and ... the five years to 2019. The 2009 Health ... established Medicare and Medicaid incentives to encourage the ...
(Date:9/21/2014)... Originally approved by the Food ... (fluticasone propionate) is a synthetic ICS therapy with ... maintenance treatment of asthma prophylactically in children and ... Diskus and HFA, which received the FDA approval ... fluticasone propionate, can bind to glucocorticoid receptors with ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 More ... have been added over the past month to ... allege serious cardiovascular injuries caused by the dialysis ... List updated on September 15th shows 2,089 cases ... U.S. District Court, District of Massachusetts. These claims ...
(Date:9/21/2014)... Aliso Viejo, California (PRWEB) September 21, 2014 ... Pro X plugins have announced a new transition ... , “Transpack Vol. 3 delivers high quality transitions that ... video project,” said Christina Austin, CEO of Pixel Film ... Vol. 3 is a definite game changer.” , Transpack ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, has recently announced ... most recommended hosting suppliers for the webmasters worldwide ... , “Don’t waste your time on searching ... hosting companies to you,” the IT manager of ... are the most recommended suppliers for everyone. A ...
Breaking Medicine News(10 mins):Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2
... , NEW YORK, ... research report is available in its catalogue: , ... http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth review of ... , Offer an analysis of antibiotics resistance from an ...
... angioplasty within 90 minutes of hospital arrival, study finds ... program to get faster treatment for people with the ... the time between hospital arrival and lifesaving angioplasty. , ... -- so called because of the electrocardiogram pattern that ...
... more to come, NIH director says, , WEDNESDAY, Dec. 2 ... added to the pool that scientists can use for taxpayer-funded ... available, U.S. health officials announced Wednesday. , These are the ... by the U.S. National Institutes of Health (NIH) since President ...
... , ... Represent Diverse Healthcare Stakeholders , WASHINGTON, Dec. 2 ... new members to its Board of Directors and reappointed four current ... healthcare stakeholders, including consumers, providers, purchasers and suppliers, and public and ...
... , KNOXVILLE, Tenn., Dec. 2 ... with the acquisition of Naples-based Emergency Physicians of Naples, LLC ... contract with NCH Healthcare System to staff the emergency facilities ... Marco Healthcare Clinic. EPN also provides the staffing for two ...
... Constraint-induced movement therapy (CIMT) is a potentially effective ... but more research is needed, according to a new ... Physical Therapy (PTJ), the scientific journal of the ... 21 intervention studies and 2 systematic reviews, concluded that ...
Cached Medicine News:Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:Heart Attack Treatment Speeds Up Nationwide 2Health News:Heart Attack Treatment Speeds Up Nationwide 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: